Revenue - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	12 Months Ended
	Jul. 13, 2020	Jul. 13, 2020	Jan. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
License And Collaboration Agreements [Line Items]
Deferred revenue recognized				$ 112,000	$ 202,000	$ 7,000
Total collaboration and license revenues				$ 112,000	$ 383,000	$ 78,000
Net loss per share, diluted				$ (3.71)	$ 0.71	$ (2.24)
Remaining capitalized fees at closing				$ 4,000
Fees allocated among performance obligations				8,000
Gilead
License And Collaboration Agreements [Line Items]
Fee incurred to third party upon receipt of option exercise payments				4,000
Capitalized costs				1,000	$ 4,000	$ 1,000
Cost sharing receivable				4,000
Gilead | Prepaid Expenses and Other Current Assets
License And Collaboration Agreements [Line Items]
Capitalized Contract Cost, Net, Current				1,000
Gilead | Other Noncurrent Assets
License And Collaboration Agreements [Line Items]
Capitalized Contract Cost, Net, Noncurrent				$ 3,000
Customer Concentration Risk | Revenue Benchmark | Gilead
License And Collaboration Agreements [Line Items]
Percentage of revenues				96.00%	94.00%	91.00%
Amended Gilead Collaboration Agreement
License And Collaboration Agreements [Line Items]
Upfront cash payment				$ 725,000
Deferred revenue				165,000
Option continuation payment due upon second anniversary of agreement				100,000
Initial transaction price				890,000
Option payments received			$ 725,000
Gilead Collaboration Agreement
License And Collaboration Agreements [Line Items]
Deferred revenue				452,000	$ 559,000
Total collaboration and license revenues				$ 4,000
Net loss per share, diluted				$ 0.06
Option payment upon achievement of certain development milestones				$ 150,000
Gilead Collaboration Agreement | Gilead
License And Collaboration Agreements [Line Items]
Deferred revenue				185,000
Option payment upon achievement of certain development milestones	$ 275,000
Deferred revenue related to domvanalimab option				37,000
Deferred revenue recognized					329,000
Total collaboration and license revenues				34,000	0
Option payment upon achievement of certain development milestones		$ 250,000
Deferred revenue related to etrumadenant option				127,000
Deferred revenue related to access rights and option				92,000
Current and future programs exclusive access period	10 years
Contingent milestone payments receivable	$ 300,000	300,000
Option continuation payment receivable upon sixth anniversary of agreement	100,000	$ 100,000
Contractual obligation remaining amount not obligated to pay	$ 300,000
Performance obligation period	4 years
Consultant and legal fees	$ 7,000
Domvanalimab R&D services
License And Collaboration Agreements [Line Items]
Deferred revenue				30,000
Total collaboration and license revenues				5,000	0
R&D and Commercialization Activities for Zimberelimab
License And Collaboration Agreements [Line Items]
Deferred revenue				1,000
Total collaboration and license revenues				9,000	1,000
Deferred revenue related to development and commercialization services				10,000
Quemliclustat, License and R&D services
License And Collaboration Agreements [Line Items]
Option payment upon achievement of certain development milestones				200,000
Quemliclustat, License and R&D services | Gilead
License And Collaboration Agreements [Line Items]
Deferred revenue				149,000
Total collaboration and license revenues				26,000	0
Zimberelimab License
License And Collaboration Agreements [Line Items]
Deferred revenue recognized						$ 55,000
Stock Purchase Agreement
License And Collaboration Agreements [Line Items]
Direct offering cost	$ 2,000
Access rights and option continuation periods
License And Collaboration Agreements [Line Items]
Deferred revenue				87,000
Total collaboration and license revenues				$ 33,000	$ 31,000	$ 16,000